Rho kinase Inhibitors
2 drugsAbout Rho kinase
Rho kinase (ROCK) is a serine/threonine kinase involved in various cellular processes, including cell motility, adhesion, and contraction. It regulates actin cytoskeleton dynamics by phosphorylating downstream targets. ROCKs are attractive drug targets due to their involvement in multiple disease pathways.
Currently, there is no genetic evidence directly linking ROCK to specific diseases. However, the existence of two FDA-approved drugs targeting ROCK validates its therapeutic potential. This suggests that modulating ROCK activity can achieve clinical benefit.
Two FDA-approved drugs, RHOPRESSA and NETARSUDIL MESYLATE, target ROCK, both are small molecule inhibitors. These drugs, developed by Novartis and GLAND PHARMA LTD, are currently approved for 'other' therapeutic areas.
Top Rho kinase Drugs
The competitive landscape includes two companies, Novartis and GLAND PHARMA LTD, with approved ROCK-targeting drugs.
The limited number of players suggests relatively low competition, but also potentially high barriers to entry.
Rho kinase Drug Modality Landscape
Modalities
Routes of Administration
Rho kinase is druggable by small molecules, though no oral formulations are currently approved.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing small molecule inhibitors.
Rho kinase Clinical Trials 28 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Rho kinase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 | 100% |
| Phase 2 | 11 | 9 | 1 | 1 | 90% |
| Phase 3 | 6 | 6 | 0 | 0 | 100% |
| Phase 4 | 9 | 3 | 0 | 6 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Rho kinase Drug Approval Timeline (2017 - 2017)
The first and most recent ROCK-targeting drug, RHOPRESSA, was approved in 2017.
The recent approval suggests renewed interest in ROCK inhibition, but also indicates a potentially saturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 15 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Rho kinase. A trial counts if an approved drug acting on Rho kinase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.